The amazing results showed that AKI was significantly reduced with RIPC (45/120; 37.5%) compared with control (63/120; 52.5%), with an absolute risk reduction (ARR) of 15%. Fewer patients received RRT after RIPC (7 [5.8%] vs 19 control [15.8%]; ARR, 10%) and RIPC reduced intensive care unit stay (3 vs 4 days). RIPC had no significant effect on myocardial infarction, stroke, or mortality.
Can we start using this in clinical practice? It is innovative, inexpensive and easily possible. But long terms risks and harms are not known. Clearly, there is significant risk of AKI post CABG and this might be the only preventive measure that we have that has come close to showing any benefit.
As suggested by the editorial in JAMA, before RIPC is adopted for clinical use, the potential risks and adverse effects must be considered carefully.